



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Early support to innovation

Session 1: EMA's support for SMEs developing innovative veterinary medicines

Veterinary Info Day for micro, small and medium-sized enterprises (SMEs): EMA support for SMEs under the new Veterinary Medicinal Products Regulation

Presented by Frida Wikström on 28 October 2021
Chair of SAWP-v, CVMP member




LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

An agency of the European Union






EMA's support for SMEs developing innovative veterinary medicines





Scientific Advice Working Party (vet)



Working party to CVMP

15 members including chair and vice-chair, 13 also members/alternates of CVMP

Expertise to cover most areas

Meetings every month (except Aug) in the margins of CVMP meetings




Provides recommendations to the CVMP on all matters relating directly or indirectly to all scientific aspects of veterinary medicinal products, including maximum residue limits (MRLs) and on questions of a more general scientific nature (including minor use minor species (MUMS) applications) pertaining to veterinary medicinal products




EMA




SAWP-v



CVMP



60 – 90 days





Example

The product is a cell therapy intended for treatment of dogs. A preliminary dose determination study and a pivotal field trial are planned (protocols provided). Will the planned studies be appropriate to address efficacy?

Scientific
Advice

Scientific discussion on study design and data requirements for an upcoming application for marketing authorisation. Possibility to discuss aspects not addressed in guidance and make recommendations on e.g.

- Study groups – control group, number and size of groups, doses
- Endpoints, tested parameters
- Specific issues for product type and indication
- 3Rs



Example

The product is a new live vaccine against a zoonotic viral disease. How should safety be addressed, is there a possibility to make a theoretical assessment of risk of reassortment or is proprietary data necessary?

Scientific
Advice

Scientific discussion on the specific risks for the vaccine and how these should be addressed in an application for marketing authorisation.



Example

The active substance is of biological origin and the mechanism of action is by non-specific immunomodulation. What data (dossier structure) will be required for safety and efficacy in an application for marketing authorisation?

Regulatory
Advice

Data requirements, type of studies and dossier structure differ depending on classification of the product as immunological or biological

Classification requests are **regulatory issues** – to be addressed by EMA/CVMP



Example

The product is of biological origin and is similar to an already authorised product in the EU. Is a hybrid application appropriate?

Regulatory
Advice

Legal basis of the application is a **regulatory issue** – to be addressed by EMA

However...

Questions relating to how similarity should be demonstrated and data requirements for the product are **scientific issues** – to be addressed by Scientific Advice



Example

A product with a protein as active substance is under development. One point for consideration and discussion concerns the use of novel bioassays (anti-drug antibodies (ADAs), potency, stability) to fully characterise the protein.

**Innovation
Task Force**

Questions during early product development to aid in strategic decisions

Discussion forum with experts

Opinions expressed are those of experts, not of CVMP



How to phrase questions in Scientific Advice requests

Clear and specific

Provide relevant background information (summarised and in annexes)

The following studies (included as annexes) have been performed and published literature is available (included as annexes) to support efficacy of treatment. Is the data presented sufficient to accept efficacy for the intended indication?



SAWP-v/CVMP **cannot assess and conclude on data within the scope of a Scientific Advice**, this is done in the context of an application for marketing authorisation where the full data set is presented in the dossier



Further information

www.ema.europa.eu

IRIS – technical platform for submission of requests

Dates for submission

Guidance documents and templates



Search

Medicines ▾ Human regulatory ▾ Veterinary regulatory ▾ Committees ▾ News & events ▾ Partners & networks ▾ About us ▾

Veterinary regulatory

Overview

Research and development

Marketing authorisation

Post-authorisation

Availability of veterinary vaccines

Compliance

Ethical use of animals

Innovation in medicines

Maximum residue limits

Veterinary limited markets

Quality by design

Scientific advice

Scientific guidelines

Scientific advice [← Share](#)

Table of contents

- [Apply using the 'IRIS' platform](#)
- [Guidance documents and templates](#)

The European Medicines Agency can give scientific advice to companies on the appropriate tests and studies in the development of a veterinary medicine. This is designed to facilitate the development and availability of high-quality, effective and acceptably safe medicines.

For veterinary medicines, scientific advice is given by the Committee for Medicinal Products for Veterinary Use (CVMP) on the recommendation of the Scientific Advice Working Party (SAWP).

Information on fees payable for scientific advice can be found under fees.

[Apply using the 'IRIS' platform](#)





Any questions?

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**